Compare GSK plc (GSK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.53. The key difference: GSK plc pays a 3.49% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and GSK plc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| GSK | QDTE | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $36.60 |
52-Week Low | $36.20 | $26.85 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
